학술논문
A Mouse Model with a Frameshift Mutation in the Nuclear Factor I/X (NFIX) Gene Has Phenotypic Features of Marshall‐Smith Syndrome
Document Type
Academic Journal
Author
Kooblall, Kreepa G.; Stevenson, Mark; Stewart, Michelle; Harris, Lachlan; Zalucki, Oressia; Dewhurst, Hannah; Butterfield, Natalie; Leng, Houfu; Hough, Tertius A.; Da; Siow, Bernard; Potter, Paul; Cox, Roger D.; Brown, Stephen D.M.; Horwood, Nicole; Wright, Benjamin; Lockstone, Helen; Buck, David; Vincent, Tonia L.; Hannan, Fadil M.; Bassett, J.H. Duncan; Williams, Graham R.; Lines, Kate E.; Piper, Michael; Wells, Sara; Teboul, Lydia; Hennekam, Raoul C.; Thakker, Rajesh V.
Source
JBMR Plus. June 2023, Vol. 7 Issue 6
Subject
Language
English
Abstract
Introduction The nuclear factor I/X (NFIX) gene (MIM #164005),[sup.(] [sup.1–3] [sup.)] located on chromosome 19p13.2,[sup.(] [sup.4] [sup.)] consists of 11 exons (Fig. S1) that encode 14 transcripts, of which 11 [...]
The nuclear factor I/X (NFIX) gene encodes a ubiquitously expressed transcription factor whose mutations lead to two allelic disorders characterized by developmental, skeletal, and neural abnormalities, namely, Malan syndrome (MAL) and Marshall–Smith syndrome (MSS). NFIX mutations associated with MAL mainly cluster in exon 2 and are cleared by nonsense‐mediated decay (NMD) leading to NFIX haploinsufficiency, whereas NFIX mutations associated with MSS are clustered in exons 6–10 and escape NMD and result in the production of dominant‐negative mutant NFIX proteins. Thus, different NFIX mutations have distinct consequences on NFIX expression. To elucidate the in vivo effects of MSS‐associated NFIX exon 7 mutations, we used CRISPR‐Cas9 to generate mouse models with exon 7 deletions that comprised: a frameshift deletion of two nucleotides (Nfix Del2); in‐frame deletion of 24 nucleotides (Nfix Del24); and deletion of 140 nucleotides (Nfix Del140). Nfix[sup.+/Del2], Nfix[sup.+/Del24], Nfix[sup.+/Del140], Nfix[sup.Del24/Del24], and Nfix[sup.Del140/Del140] mice were viable, normal, and fertile, with no skeletal abnormalities, but Nfix[sup.Del2/Del2] mice had significantly reduced viability (p < 0.002) and died at 2–3 weeks of age. Nfix Del2 was not cleared by NMD, and Nfix[sup.Del2/Del2] mice, when compared to Nfix[sup.+/+] and Nfix[sup.+/Del2] mice, had: growth retardation; short stature with kyphosis; reduced skull length; marked porosity of the vertebrae with decreased vertebral and femoral bone mineral content; and reduced caudal vertebrae height and femur length. Plasma biochemistry analysis revealed Nfix[sup.Del2/Del2] mice to have increased total alkaline phosphatase activity but decreased C‐terminal telopeptide and procollagen‐type‐1‐N‐terminal propeptide concentrations compared to Nfix[sup.+/+] and Nfix[sup.+/Del2] mice. Nfix[sup.Del2/Del2] mice were also found to have enlarged cerebral cortices and ventricular areas but smaller dentate gyrus compared to Nfix[sup.+/+] mice. Thus, Nfix[sup.Del2/Del2] mice provide a model for studying the in vivo effects of NFIX mutants that escape NMD and result in developmental abnormalities of the skeletal and neural tissues that are associated with MSS. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
The nuclear factor I/X (NFIX) gene encodes a ubiquitously expressed transcription factor whose mutations lead to two allelic disorders characterized by developmental, skeletal, and neural abnormalities, namely, Malan syndrome (MAL) and Marshall–Smith syndrome (MSS). NFIX mutations associated with MAL mainly cluster in exon 2 and are cleared by nonsense‐mediated decay (NMD) leading to NFIX haploinsufficiency, whereas NFIX mutations associated with MSS are clustered in exons 6–10 and escape NMD and result in the production of dominant‐negative mutant NFIX proteins. Thus, different NFIX mutations have distinct consequences on NFIX expression. To elucidate the in vivo effects of MSS‐associated NFIX exon 7 mutations, we used CRISPR‐Cas9 to generate mouse models with exon 7 deletions that comprised: a frameshift deletion of two nucleotides (Nfix Del2); in‐frame deletion of 24 nucleotides (Nfix Del24); and deletion of 140 nucleotides (Nfix Del140). Nfix[sup.+/Del2], Nfix[sup.+/Del24], Nfix[sup.+/Del140], Nfix[sup.Del24/Del24], and Nfix[sup.Del140/Del140] mice were viable, normal, and fertile, with no skeletal abnormalities, but Nfix[sup.Del2/Del2] mice had significantly reduced viability (p < 0.002) and died at 2–3 weeks of age. Nfix Del2 was not cleared by NMD, and Nfix[sup.Del2/Del2] mice, when compared to Nfix[sup.+/+] and Nfix[sup.+/Del2] mice, had: growth retardation; short stature with kyphosis; reduced skull length; marked porosity of the vertebrae with decreased vertebral and femoral bone mineral content; and reduced caudal vertebrae height and femur length. Plasma biochemistry analysis revealed Nfix[sup.Del2/Del2] mice to have increased total alkaline phosphatase activity but decreased C‐terminal telopeptide and procollagen‐type‐1‐N‐terminal propeptide concentrations compared to Nfix[sup.+/+] and Nfix[sup.+/Del2] mice. Nfix[sup.Del2/Del2] mice were also found to have enlarged cerebral cortices and ventricular areas but smaller dentate gyrus compared to Nfix[sup.+/+] mice. Thus, Nfix[sup.Del2/Del2] mice provide a model for studying the in vivo effects of NFIX mutants that escape NMD and result in developmental abnormalities of the skeletal and neural tissues that are associated with MSS. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.